Q-omics provides the consensus-scored CPS1-IT1 profile across patient tissues and cancer cell-line models. CPS1-IT1 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, CPS1-IT1 is differentially expressed in 3, with the highest sampling consensus in LIHC. Additionally, CPS1-IT1 RNA expression shows 7,253 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight LUAD, LIHC, and ESCA as cancer lineages where CPS1-IT1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CPS1-IT1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CPS1-IT1 survival associations across molecular data types. CPS1-IT1 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CPS1-IT1 RNA expression–survival associations across cancer types. High CPS1-IT1 expression shows unfavorable associations in LUAD, KIRP, READ, ESCA and CHOL, but favorable associations in LIHC. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for CPS1-IT1 RNA expression.
This table summarizes CPS1-IT1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for CPS1-IT1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CPS1-IT1 shows lower tumor expression in LIHC and CHOL and higher tumor expression in LUAD. The LIHC box plot shows higher CPS1-IT1 RNA expression in normal versus tumor tissue (log2 FC = −0.208, t-test p = .010).
This table shows molecular features associated with CPS1-IT1 in patient tissues and cancer cell lines. In patient samples, CPS1-IT1 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, CPS1-IT1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BREAST.
